Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers

Journal of Clinical Pharmacology

Volumn 39, Issue 1, 1999, Pages 91-96

  Hebert, Mary F ^a   Fisher, Richard M ^a   Marsh, Christopher L ^b   Dressler, Dawna ^c   Bekersky, Ihor ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; RIFAMPICIN; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; ENZYME INDUCTION; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; LIVER; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; SMALL INTESTINE; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; INTESTINES; LIVER; MALE; METABOLIC CLEARANCE RATE; RIFAMPIN; TACROLIMUS;

EID: 0032895989     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922007499     Document Type: Article

References (24)

1. Rinaldi M, Pellegrini C, Martinelli L, Goggi C, Gavazzi A, Campana C, et al: FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study. J Heart Lung Transplant 1997;16:1001-1010.
2. Asfar S, Atkison P, Ghent C, Duff J, Wall W, Williams S, et al: Small bowel transplantation: a life-saving option for selected patients with intestinal failure. Dig Dis Sci 1996;41:875-883.
3. Sattler M, Guengerich FP, Yun C-H, Christians U, Sewing KF: Cytochrome P-450A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992;20:753-761.
4. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T: Human p-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993;268:6077-6080.
5. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ: Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992;52:453-457.
6. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS: The erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J Clin Invest 1989;83:688-697.
7. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB: Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-1878.
8. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of p-glycoprotein and cytochrome P450 3A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996;49:311-318.
9. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, et al: Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995;58:492-497.
10. Mekki Q, Lee C, Carrier S, Klintmalm G, Schaefer M, Burke P, et al: The effect of food on oral bioavailability of tacrolimus (FK506) in liver transplant patients. Clin Pharmacol Ther 1993;53:229.
11. Dressler D, Bekersky I, Lee J, Tracewell WG, Kisicki J, Mekki Q: Effect of meal time on tacrolimus bioavailability. Clin Pharmacol Ther 1996;59:151.
12. Lee JW, Sukovaty RL, Farmen RH, Dressler DE, Alak A, Bekersky I: Tacrolimus (FK506): validation of a sensitive enzyme-linked immunosorbent assay kit for and application to a clinical pharmacokinetic study. Ther Drug Monit 1997;19:201-207.
13. Ishii M, Ogata H: Determination of rifampicin and its main metabolites in human plasma by high-performance liquid chromatography. J Chromatogr 1988;426:412-416.
14. Jamaluddin ABM, Sarwar G, Rahim MA, Rahman MK: High-performance liquid chromatographic assay of rifampicin in human serum. J Chromatogr 1990;525:495-497.
15. Benet LZ, Galeazzi RL: Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 1979;68:1071-1074.
16. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, et al: First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996;60:14-24.
17. Benet LZ, Wu CY, Hebert MF, Wacher VJ: Intestinal drug metabolism and antitransport processes: a potential paradigm shift in oral drug delivery. J Control Rel 1996;39:139-143.
18. Reichel C, Block W, Skodra T, Traber F, Schiedermaier P, Spengler U, et al: Relationship between cytochrome P-450 induction by rifampicin, hepatic volume and portal blood flow in man. Eur J Gastroenterol Hepatol 1997;9:975-979.
19. Furlan V, Perello L, Jacquemin E, Debray D, Taburet A-M: Interaction between FK506 and rifampicin or erythromycin in pediatric liver recipients. Transplantation 1995;59:1217-1218.
20. Schuetz EG, Schuetz JD, Strom SC, Thompson MT, Fisher RA, Molowa DT, et al: Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology 1993;18:1254-1262.
21. Williams JA, Chenery RJ, Hawksworth GM: Induction of CYP3A enzymes in human and rat hepatocyte cultures. Biochem Soc Trans 1994;22:131S.
22. Coward RA, Raftery AT, Brown CB: Cyclosporine and antituberculous therapy. Lancet 1985;1:1342-1343.
23. Daniels NJ, Dover JS, Schachter RK: Interaction between cyclosporine and rifampicin. Lancet 1984;2:639.
24. Vandevelde C, Chang A, Andrews D, Riggs W, Jewesson P: Rifampin and ansamycin interactions with cyclosporine after renal transplantation. Pharmacotherapy 1991;11:88-89.